EBITDA: Income before interest, taxes, depreciation and amortization.
Vaxcyte, Inc. (PCVX) had EBITDA of $-343.11M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-320.62M |
|
-- |
|
-- |
|
$345.85M |
|
$-345.85M |
|
$25.23M |
|
$-320.62M |
|
$-320.62M |
|
$-320.62M |
|
$-320.62M |
|
$-320.62M |
|
$-320.62M |
|
$-345.85M |
|
|
EBITDA |
$-343.11M |
139.51M |
|
139.51M |
|
$-2.30 |
|
$-2.30 |
|
| Balance Sheet Financials | |
$1.81B |
|
$260.69M |
|
$1.53B |
|
$3.35B |
|
$242.08M |
|
-- |
|
$110.21M |
|
$352.29M |
|
$3.00B |
|
$3.00B |
|
$3.00B |
|
144.31M |
|
| Cash Flow Statement Financials | |
$-280.62M |
|
$-233.41M |
|
$601.58M |
|
$175.43M |
|
$262.31M |
|
$86.88M |
|
$37.96M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.49 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-282.73M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-10.70% |
|
-10.70% |
|
-9.58% |
|
-10.70% |
|
$20.76 |
|
$-2.03 |
|
$-2.01 |
|